Gross Profit Comparison: Ascendis Pharma A/S and MorphoSys AG Trends

Biotech Giants: Ascendis vs. MorphoSys Profit Trends

__timestamp	Ascendis Pharma A/S	MorphoSys AG
Wednesday, January 1, 2014	13983000	63900978
Thursday, January 1, 2015	8118000	106145897
Friday, January 1, 2016	4606000	49646515
Sunday, January 1, 2017	1530000	66757840
Monday, January 1, 2018	10581000	74645876
Tuesday, January 1, 2019	13375000	59670105
Wednesday, January 1, 2020	6953000	318524319
Friday, January 1, 2021	4255000	147400000
Saturday, January 1, 2022	39037000	229647003
Sunday, January 1, 2023	222323000	179923313
Monday, January 1, 2024	319383000

Data in motion

A Tale of Two Biotechs: Ascendis Pharma A/S vs. MorphoSys AG

In the dynamic world of biotechnology, Ascendis Pharma A/S and MorphoSys AG have carved distinct paths over the past decade. From 2014 to 2023, MorphoSys AG consistently outperformed Ascendis Pharma in gross profit, peaking in 2020 with a staggering 318% increase from its 2016 figures. However, Ascendis Pharma made a remarkable leap in 2023, achieving a gross profit surge of over 5,600% compared to its 2017 low. This dramatic rise highlights Ascendis Pharma's strategic advancements and market adaptability. Meanwhile, MorphoSys AG's steady growth underscores its robust business model and sustained market presence. As these two companies continue to innovate, their financial trajectories offer valuable insights into the evolving biotech landscape.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025